Discovery of Potent Small-Molecule SIRT6 Activators: Structure–Activity Relationship and Anti-Pancreatic Ductal Adenocarcinoma Activity

Authors:

Abstract
SIRT6 activation is thought to be a promising target for the treatment of many diseases, particularly cancer. Herein, we report the discovery of a series of new small molecule SIRT6 activators. Structure-activity relationship analyses led to the identification of the most potent compound, 2-(1-benzofuran-2-yl)-N-(diphenylmethyl) quinolone-4-carboxamide (12q), which showed an EC1.5 value of 0.58 ± 0.12 μM and an EC50 value of 5.35 ± 0.69 μM against SIRT6-dependent peptide deacetylation in Fluor de Lys assay. It exhibited weak or no activity against other HDAC family members as well as 415 kinases, indicating a good selectivity for SIRT6. 12q significantly inhibited the proliferation and migration of pancreatic ductal adenocarcinoma (PDAC) cells in vitro. It also markedly suppressed the tumor growth in a PDAC tumor xenograft model. This compound showed attractive pharmacokinetic properties. Overall, 12q could be a good lead compound for the treatment of PDAC, and it is worthy of further study.
Funding Information
  • National Natural Science Foundation of China (21772130, 81773633, 81930125)
  • Department of Science and Technology for Social Development (2018ZX09201018, 2018ZX09711002-011-019, 2018ZX09711002-014-002, 2018ZX09711003-003-006, 2019ZX09301-135)
  • 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (ZY2017202, ZYGD18001)

This publication has 56 references indexed in Scilit: